Overview

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Status:
Active, not recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Phase:

Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Methylprednisolone
Mycophenolate mofetil
Mycophenolic Acid
Obinutuzumab
Prednisone